De- “bug”-ing the microbiome in lung cancer

• Published in: Cancer and metastasis reviews Vol. 41; no. 2; pp. 335 - 346
• Main Authors: Birla, Pakhi, Shaikh, Fyza Y.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2022; Springer; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Comparative analysis; Immune response; Interleukin 17; Lung cancer; Microbiomes; Neoantigens; Oncology; Oncology, Experimental; Tumors; NSCLC; Metabolites; Lung cancer; Intra-tumoral immunity; Microbiome
• ISSN: 0167-7659; 1573-7233
• DOI: 10.1007/s10555-022-10036-4

The identification of microbes enriched in the healthy lung has led to the compelling discovery that microbes may contribute to lung cancer pathogenesis. Here, we review the recent literature showing microbial associations with lung cancer as well as the functional features that have been identified in human and murine studies. Most biomarker data remain limited due to variable findings. However, multiple studies have found that lung tumors or ipsilateral airway samples have decreased α diversity compared to normal tissue. Specific genera, such as Veillonella and Streptococcus , were also found in association with lung tumors using multiple sampling methodologies. These microbes, which are generally found in the upper respiratory track, are associated with an IL-17 signature in the lung, potentially resulting in a pro-tumorigenic environment. Studies detailing these immune mechanisms are limited, and further investigation is necessary to delineate how these bacteria, their metabolites, and potentially tumor-associated neoantigens modulate the immune response in cancer.